



Immunic Therapeutics

Developing Selective Oral Drugs in Immunology



NASDAQ: IMUX

BMO Prescriptions for Success Healthcare Conference

June 25, 2019

Cautionary Note Regarding Forward-Looking Statements

- Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunic undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.
- Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management. Risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Immunic’s plans to develop and commercialize its product candidates, including IMU-838, IMU-935 and IMU-856; the timing of initiation of Immunic’s planned clinical trials; expectations regarding potential market size; the timing of the availability of data from Immunic’s clinical trials; the timing of any planned investigational new drug application or new drug application; Immunic’s plans to research, develop and commercialize its current and future product candidates; Immunic’s ability to successfully collaborate with existing collaborators or enter into new collaboration agreements, and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of Immunic’s product candidates; Immunic’s commercialization, marketing and manufacturing capabilities and strategy; Immunic’s ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Immunic’s competitors and industry; the impact of government laws and regulations; Immunic’s ability to protect its intellectual property position; Immunic’s listing on The Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of the company; the executive and board structure of the company; Immunic’s estimates regarding future revenue, expenses, capital requirements and need for additional financing; and the nature, strategy and focus of the company.
- Forward-looking statements included in this presentation are based on information available to Immunic as of the date of this presentation. Immunic does not undertake any obligation to update such forward- looking statements to reflect events or circumstances after the date of this presentation.

Key Investment Highlights

Three potential best-in-class oral therapies

- IMU-838: Potent DHODH inhibitor currently tested in two phase 2 studies
- IMU-935: High demand target with substantial potential
- IMU-856: Novel target – potentially disease modifying for IBD

Strong IP position

- IMU-838: Granted patents **until 2031**, patent application coverage **until 2038**
- IMU-935: **New compound IP** filed in 2017
- IMU-856: Compound patent filed in 2018

High value markets

- Autoimmune & immunology with **high unmet medical needs**
- **Large markets** for IBD, MS and psoriasis with multibillion USD sales potential
- Well financed with cash runway to near-term value-driving events


Experienced global management team

- Experienced management team with strong track record and over 70 years of leadership experience in the pharmaceutical industry
- Headquartered in the US with R&D operations in Munich, Germany

Successful deal created IMUX

- Ticker symbol: **IMUX**
- Shares outstanding: 9.9 million (as of April 12, 2019)
- Cash position: 46.7 million USD (as of April 12, 2019)
- Cash expected to last into Q3/2020

Development Pipeline



MS Opportunity

Aubagio® (teriflunomide) is currently the **only approved DHODH inhibitor** for MS

Despite its substantial side effects, Aubagio® reached sales of **around 1.8 billion USD in 2018**^[1]

IMU-838 has the potential to be a **best-in-class DHODH inhibitor** and **MS drug** due to improved safety and pharmacokinetics profile

Significant News Flow Potential From Three Development Projects



- ➤ FPI phase 2 IMU-838 in RRMS
- FPI phase 2 IMU-838 in PSC / IST at Mayo Clinic expected
- ➤ Interim dosing analysis phase 2 IMU-838 in UC expected
- FPI phase 2 IMU-838 in CD expected
- FPI phase 1 SAD IMU-935 expected
- Phase 1 data SAD IMU-935 expected
- ➤ LPI phase 2 IMU-838 in RRMS expected
- FPI phase 1 MAD IMU-935 expected
- FPI phase 1 SAD IMU-856 expected
- Phase 1 data MAD IMU-935 expected
- ➤ LPI phase 2 IMU-838 in UC expected
- Top-line results phase 2 IMU-838 in RRMS expected
- ➤ Top-line results phase 2 IMU-838 in UC expected

Financial Status and Cash Runway

- Nasdaq: **IMUX**
- Headquarters in San Diego – plan to relocate to East Coast in 2019
- Shares outstanding: 9.9 million (as of April 12, 2019)
- Cash position of 46.7 million USD (as of April 12, 2019)
- Cash runway expected to be sufficient beyond important value inflection points into Q3/2020
- Immunic’s reverse takeover with Vital Therapies was supported by a committed investor base investing approximately 30 million USD in April 2019







Thank You!

Immunic, Inc.

11440 West Bernardo Court, Suite 300

San Diego, CA 92127

USA

Jessica Breu

Manager IR & Communications

Phone: +49 89 250 0794 69

Email: jessica.breu@immunic.de